The global cytokine release syndrome management market is expected to reach USD 23.32 Billion in 2023 and is projected to exhibit a CAGR of 6.7% from 2023 to 2033. A growing number of autoimmune diseases and cancers is expected to result in an increase in the market for CRS management in the coming years.
A new generation of drugs such as tocilizumab, siltuximab, and anakinra have revolutionized the treatment of Cytokine Release Syndrome (CRS). Using these drugs can reduce the severity of CRS by reducing the production of pro-inflammatory cytokines. Symptoms associated with CRS can also be reduced with aggressive supportive care, such as fluid resuscitation, anti-emesis, and anti-diarrhea medication. CRS can be treated early and prevent long-term complications by recognizing it early and treating it promptly.
A very promising future lies ahead for the management of cytokine release syndrome. Symptoms of cytokine release syndrome are increasingly being treated and managed through immunotherapy treatments. Additionally, there are numerous studies that are being conducted to better understand the underlying mechanisms that cause cytokine release syndrome, as well as the potential treatment options available for the disease. There is therefore an increasing likelihood that effective interventions will be available in the future. As a result, the outlook for the management of cytokine-release syndromes in the near future is promising.
| Data Points | Key Statistics |
|---|---|
| Estimated Base Year Value (2022) | USD 22 Billion |
| Expected Market Value (2023) | USD 23.32 Billion |
| Anticipated Forecast Value (2033) | USD 44.6 Billion |
| Projected Growth Rate (2023 to 2033) | 6.7% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global demand for cytokine release syndrome management is projected to increase at a CAGR of 5.2% during the forecast period between 2023 and 2033, reaching a total of USD 5 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 4%.
In the intervening years, the treatment and prevention of COVID-19 disease have progressed greatly since the start of the SARS-CoV-2 pandemic. COVID-19 can be treated with diverse therapies, including antiviral small molecule drugs, immune modulators, cell and gene therapies, neutralizing antibodies, and combination therapies. The most studied of these treatments are immunomodulators. As these drugs target conservative parts of the virus or common pathways of inflammation, the immunoregulators and small-molecule antivirals are likely to be effective against SARS-CoV-2.
In spite of the fact that immunoregulators have reduced mortality associated with cytokine release syndrome (CRS) caused by SARS-CoV-2 infections, novel therapies with increased efficacy and reduced side effects are still needed. Chimeric antigen receptor T cell therapy has recently attracted widespread attention in the field of adoptive immunotherapy. Cells derived from CAR-Ts are considered living drugs, which can exist in the body for years and possess antitumor properties.
Cytokine Release Syndrome Therapies are driving Market Growth
CAR-T therapy, which targets cancer cells with chimeric antigen receptors, is expected to drive market growth. A study of the global CAR-T cell therapy market published in the Journal of Clinical Oncology estimates that the market will reach USD 6.3 billion by 2026. Several types of cancer are treated with this therapy, leading to the development of cytokine release syndrome (CRS). In order to manage cytokine release syndrome, the use of CAR-T therapy is expected to increase, which will drive the demand for the management of the syndrome.
As new treatments and diagnostics for CRS are developed, including monoclonal antibodies and inhibitors of the interleukin-6 system, better ways are being found to ward off the disease. Increasing awareness of CRS among medical professionals has led to an increase in the need for management strategies. With the rise of personalized medicine, it has become increasingly apparent that custom-made management plans for CRS have become increasingly apparent and are now considered a necessity by management eminent experts. It is imperative that organizations develop strategies for managing CRS and its associated risks as they integrate patient-centric care into their operations.
Growing Opportunities will drive Future Market Growth for Cytokine Release Syndrome Management
The CRS management market is estimated to grow significantly during the forecast period (2022 to 2033). The growth of the CRS market is attributed both to the growing number of pipeline drugs as well as the growing awareness about the CRS in the general public and among healthcare professionals. Increasing incidences of hematological malignancies, such as multiple myeloma, leukemia, and lymphoma, are projected to drive the growth of the market in the coming years.
It is estimated that the number of Americans affected by cancer will increase from 1.8 million by 2020 to 2.3 million by 2030, according to the Centers for Disease Control and Prevention (CDC). Considering the rise in the number of patients, it is expected that the demand for CRS management will increase. Moreover, a growing number of clinical trials is expected to contribute to the growth of the CRS management market. There are currently more than thirty clinical trials in progress that are being conducted to manage CRS symptoms. New and more effective treatment options for CRS are expected to be introduced as a result of the growing number of clinical trials.
Ineffective Treatment and Side Effects Limit the Market
Some cancer treatments can lead to a life-threatening condition called Cytokine Release Syndrome (CRS). Several factors impede CRS management. CRS is not widely recognized as a distinct condition and, as a result, its definition and diagnosis are unclear. It is therefore challenging to identify, assess, and treat CRS accurately.
In order to identify which patients are at higher risk of developing CRS, there is a lack of reliable biomarkers that can be used to predict their risk. Current treatment options for CRS are often difficult to obtain and are often expensive. It is generally agreed that there is no effective treatment available for CRS. Furthermore, there are insufficient resources for managing CRS, like funds and personnel, which results in the lack of adequate support.
Approvals of New Drugs and Drug Development are driving the Market Demand
North American markets for cytokine release syndrome management are expected to grow significantly during the forecast period. According to the forecast, the market is expected to accumulate a revenue share of 17% between 2023 and 2033. As the number of drug approvals for cytokine release syndrome (CRS) increases, the prevalence of cancer and other chronic diseases increases, and personalized medicine increases, the North American cytokine release syndrome (CRS) management market is expected to grow significantly over the forecast period.
In addition, novel monoclonal antibodies and small-molecule drugs are expected to contribute to the growth of the market. CRS management in North America is projected to grow as a result of an increasing number of clinical trials and collaborations between key players in the industry. The cytokine release syndrome management market in North America is predicted to grow rapidly in the next few years.
Several factors are contributing to the growth of the North American cytokine release syndrome management market, including the rising prevalence of cytokine release syndrome, an increased focus on autoimmune diseases, and the availability of novel treatments. A growing number of clinical trials for cytokine release syndrome are being conducted, and new therapies are being developed by biotechnology companies and pharmaceutical companies.
Establishment of Healthcare Infrastructure in the Region to Accelerate Market Growth
Europe's market for cytokine release syndrome management is expected to grow significantly. As cancer prevalence increases and immunotherapies are increasingly used, this market is expected to grow. The availability of skilled personnel and diagnostic equipment may lead to significant developments in Europe. Consequently, the global market for the management of cytokine release syndrome is expected to grow substantially.
There are a number of reasons contributing to the region's substantial share in the healthcare market, including the presence of an established health infrastructure, the region is characterized by a high level of healthcare spending, superior reimbursement rules, the availability of qualified specialists, advanced genetic testing equipment, and high healthcare spending.
Additionally, a growing number of clinical trials have been conducted over the last few years, and the introduction of advanced therapies, such as CAR-T therapy and biotherapies, has also been expected to contribute to the growth of the market. Other factors contributing to the growth of the cytokine release syndrome management market in Europe include favorable government regulations, funding for research, and the growing awareness about immunotherapies.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
TNF Segment Enhances Cytokine Release Syndrome Management Growth
Tumour Necrosis Factor-TNF is projected to grow at a CAGR of 2.9% from 2023 to 2033. New technologies and more public awareness are expected to boost industry growth over the next few years. The use of this therapy is increasing as a direct result of cytokine release syndrome (CRS), which is an adverse reaction associated with some cancer treatments.
The use of TNF is being employed to treat CRS by inhibiting the production of pro-inflammatory cytokines, such as IL-6, TNF-r, and interferon-r. Infliximab and etanercept are commonly used in conjunction with corticosteroids for the treatment of CRS. Patients with cancer are receiving TNF inhibitors in conjunction with other treatments to reduce their risk of developing CRS.
For example, TNF inhibitors can help reduce CRS risk when taken in conjunction with corticosteroids. Researchers are also looking into the possibility of using TNF inhibitors along with other immunosuppressants that can further decrease the chance of CRS developing, such as tocilizumab, in an effort to further reduce risks associated with the condition.
Arthritis Therapeutics to Manage Cytokine Release Syndrome
Based on the therapeutic application, the global market is segmented into cancer, asthma, airway inflammation, arthritis, and others. Forecasts indicate that arthritis revenues will surpass USD 8.7 billion in the coming years, an increase of 19% in the revenue share market.
In recent years, biological therapies have improved the quality of life for patients by dramatically reducing their reliance on pharmaceutical products. A number of biologic products are currently being evaluated in phase III trials, indicating that arthritis therapeutics manufacturers have strong commercial prospects. Inflammatory bowel disease, rheumatoid arthritis, psoriatic arthritis, and rheumatoid arthritis can all be effectively treated by blocking TNF activity.
The early detection of joint disease is key to optimizing therapeutic success. It is particularly important to perform these tests when patients have a high activity level of the disease, autoantibodies, and early joint damage that may contribute to a poor outcome, such as those with a high level of disease activity or the presence of autoantibodies. Compound indices are used to measure disease activity as part of treatment algorithms. Targeted therapies are used along with traditional antirheumatic medicines as well as biological and non-biologic agents.
Start-ups in the cytokine release syndrome management market:
Increased production and meeting consumer demands can boost manufacturers' revenue and market share. Promote new products and technologies in order to benefit end users. Strategic partnerships allow a company to become more productive by increasing its capacity as a result of forming a partnership.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 23.32 Billion |
| Market Value in 2033 | USD 44.6 Billion |
| Growth Rate | CAGR 6.7% |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Cytokine Type, Therapeutic Application, Biomarker Type, Route of Administration, End User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd; GlaxoSmithKline Plc; Novartis AG; Sanofi S.A; Pfizer Inc.; Bayer AG; Biocon; AbbVie Inc.; Johnson & Johnson Private Limited; Incyte Corporation; Swedish Orphan Biovitrum; Genentech |
| Customization | Available Upon Request |
During 2018 to 2022, the market grew at a CAGR of 4%.
Novartis AG, Pfizer Inc., and Biocon are key market players.
Growing European healthcare infrastructure drives this market.
This market is valued at USD 23.32 billion in 2023.
This market is estimated to reach USD 44.6 billion by 2033.
| Market Size (2022) | USD 13,249.2 Million |
|---|---|
| Projected Market Value (2028) | USD 17,335.8 Million |
| Market Growth Rate (2022 to 2028) | 4.6% |
Explore Therapy Area Insights
View Reports
Cytokine Release Syndrome Management Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
